ATS’ Leadership are in a Kobiyashi Maru situation with #ConferenceGate
- one one hand, they signed a terrible contract and stand to lose a ton of money if they pull out of Orlando
- the other hand, they risk having no one show up & alienating most of their members #ATSSafe4All 1/
People are angry. Seeing how many green ribbons there are at ATS, it’s dawning on ATS’ leadership that they screwed up big time.
They wonder: Will these people boycott Orlando 3 times in the next decade? Will they keep paying dues? Is this an existential threat to the org? 2/
The easiest move for the EC is to do nothing and (try to) pass the buck: If ATS implodes in 10 years after three disastrously unattended Orlando conferences will anyone remember whose fault it was?
By then EC members will have moved on to other things. Will we remember them? 3/
But remember, the Koboyashi Maru is a test of character. How do candidates face a no-win situation?
Passing the buck & leaving others to deal w/ the inevitable consequences of their decisions isn’t leadership. It fails the test.
Lead with moral conviction not
spreadsheets. 3/
ATS’ Executive Committee should lead by example:
ATS should make it clear they won’t ever hold conferences in places with unjust laws. If NAACP issues travel advisories for FL, the EC shouldn’t be going there.
Lead by setting a moral example. People will remember that. 4/
Interesting RCT in @NEJM about platelet transfusions prior to CVC placement in people w/ thrombocytopenia (Plt 10-50k):
- higher rate of grade 2-4 bleeding w/o Plt transfusion: 11.9% vs 4.9%
- difference driven by much more bleeding w/ subclavian lines nejm.org/doi/full/10.10… 1/
This trial enrolled n=338 hospitalized people in 🇳🇱 with platelets between 10-50k, INR <1.5 (changed to 3.0). 57% were heme/onc patients & 43% were ICU patients.
Median Plt count was 30k
Most were getting a CVC for chemoTx. (Most weren’t exactly your “typical” ICU patient.) 2/
Importantly they placed the CVC within 1 hour or randomization. This means they probably didn’t transfuse then place a line, more like placed a line while transfusing.
(IMO this difference matters in situations where platelets are dysfunctional, like uremia) 3/
Real shitty explanation by @atscommunity about where they plan to hold future conferences.
TL/DR: On one hand they had to consider safety & inclusion, on the other hand ATS’ sterling “reputation in the meetings industry.” They prioritized the latter.
I’m disappointed that they have prioritized profit over the concerns of members.
Frankly, I would have been willing to pay higher dues, higher conference fees, legal fees, etc if the financial concerns had been raised transparently.
Instead they decided unilaterally.
2/
A few more points to respond to:
“Who knows what the policy will be in 10 years?”
This is textbook passing the buck, a major problem in organizations with annual rotating leadership.
We ought to elect leaders who are willing to make hard decisive choices. 3/
First, this finding was driven by OR mortality, particularly in cardiac surgery patients.
ICU mortality was non-significant. (p=0.5). Additionally this is an unadjusted p-value, so if we correct for multiple comparisons it’s even more insignificant.
2/
The OR and the ICU are different places & propofol is used differently: higher doses & boluses are frequent in the OR whereas low doses with daily interruptions are common in the ICU.
In short, I don’t think it’s reasonable to extrapolate an OR finding onto an ICU population.
3/